HAE medicine specialist BioCryst buys up pharmaceutical company Astria Therapeutics to further strengthen presence in HAE

Two pharmaceutical companies with a special interest in HAE medicines, BioCryst Pharmaceuticals and Astria Therapeutics, have agreed to become a single company, with BioCryst acquiring Astria.

Astria is currently trialing a potential new preventative treatment for HAE attacks, called navenibart, which may only need to be injected every three or six months. BioCryst has long experience in HAE. The company currently markets berotralstat (Orladeyo) in many countries around the world, and has recently sold its European Orladeyo business to the Italian pharmaceutical company Neopharmed Gentili.

Jon Stonehouse, Chief Executive Officer of BioCryst, said: “We believe this transaction gives BioCryst a perfect second product candidate that fits seamlessly with our HAE core competency and enables us to build out a comprehensive portfolio that could offer the most patient-friendly option, regardless of administration preference. With our leading product, Orladeyo, and navenibart’s potentially best-in-class profile, we will be well-positioned to drive sustainable growth and profitability while optimally serving the HAE patient community.”

Jill C Milne, PhD, Chief Executive Officer of Astria Therapeutics, said: “We are thrilled to have navenibart become an integral part of BioCryst’s HAE portfolio, advancing our shared mission of empowering patients to live beyond the limitations of their disease. We have great confidence in BioCryst’s proven expertise and ability to successfully bring navenibart to patients who need better options for managing HAE and improving their quality of life.”

This deal is expected to be completed early in 2026.

(Source: BioCryst)